We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CRISPR Test Diagnoses Mpox Faster Than Lab-Based PCR Method

By LabMedica International staff writers
Posted on 14 Feb 2024
Image: CRISPR is combined with nanopore sensing technology to detect whether or not mpox is present in a sample (Photo courtesy of 123RF)
Image: CRISPR is combined with nanopore sensing technology to detect whether or not mpox is present in a sample (Photo courtesy of 123RF)

Mpox, formerly known as monkeypox, is a rare viral disease transmitted through physical contact and typically presents mild symptoms like fever, rash, and swollen lymph nodes, though severe cases can require medical intervention. Due to its contagious nature, prompt testing is crucial for isolation and treatment purposes. Current mpox testing requires laboratory equipment and may take hours to yield results. Now, new research suggests a way for faster mpox testing that could be done in any clinic.

Researchers at Pennsylvania State University (University Park, PA, USA) have utilized CRISPR, the groundbreaking gene-editing technology, to develop a faster mpox test. For their study, the team designed a genetic sequence with an attached reporter specifically targeting the mpox virus. The test employs programmable CRISPR RNA that binds to the target and a protein called Cas12a, which together cleaves the reporter to produce fragments of varying sizes. Using nanopore sensing technology, these reporter fragments are analyzed to rapidly and accurately determine the presence of mpox in a sample.

The specificity of the test was validated by its inability to detect cowpox virus, a relative of mpox, thereby confirming its exclusive sensitivity to mpox. This testing method significantly reduces the detection time, taking only 32 to 55 minutes depending on the viral load, compared to the longer duration required for PCR lab testing. The research team is exploring the application of this nanopore technology for the development of tests for other pathogens, aiming to enable multi-target testing from a single sample using a portable device. Although this technology is not yet commercially available, the researchers hope to create a device that could facilitate widespread pathogen testing.

Related Links:
Pennsylvania State University

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
All-in-One Molecular System
AIO M160

Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
ADLM